technetium-tc-99m-depreotide and Neoplasm-Metastasis

technetium-tc-99m-depreotide has been researched along with Neoplasm-Metastasis* in 2 studies

Reviews

1 review(s) available for technetium-tc-99m-depreotide and Neoplasm-Metastasis

ArticleYear
Imaging lung tumors with peptide-based radioligands.
    Clinical lung cancer, 2003, Volume: 5, Issue:2

    The somatostatin analogue octreotide was the first radiopeptide to be used for the scintigraphic diagnosis of tumors. Somatostatin receptor scintigraphy (SRS) has proven its value, especially in the detection of gut neuroendocrine tumors. In some tumor types, it is considered the diagnostic gold standard. In carcinoid tumors of the lung, SRS is of major importance in diagnostic workup. Furthermore, the combination of computed tomography scanning and SRS is a reliable and cost-effective approach for the evaluation of single pulmonary nodules. Despite these favorable properties, SRS fails in the detection of metastases of lung cancer. The problem of false-positive results in SRS resulting from inflammatory disease might be overcome by the use of new radiopeptides such as cholecystokinin-B receptor-binding gastrin analogues. This article focuses on the current status of peptide-receptor scintigraphy in the diagnosis of lung tumors and on future developments in this field.

    Topics: Cost-Benefit Analysis; Diagnosis, Differential; Gastrointestinal Agents; Humans; Lung Neoplasms; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organotechnetium Compounds; Peptides, Cyclic; Prognosis; Radionuclide Imaging; Somatostatin; Tomography, X-Ray Computed

2003

Other Studies

1 other study(ies) available for technetium-tc-99m-depreotide and Neoplasm-Metastasis

ArticleYear
Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.
    International journal of cancer, 2006, Aug-15, Volume: 119, Issue:4

    The detection of radioiodine (I-131)-negative metastases of differentiated thyroid carcinoma (DTC) has been hitherto successfully tried by the well-known synthetic somatostatin analogue indium-111-labeled DTPA-octreotide (In-111 pentetreotide). The objective of this study was to evaluate the usefulness of scintiscan with the newer synthetic somatostatin analogue Tc-99m depreotide, in the restaging of papillary thyroid carcinoma (PTC) with detectable serum thyroglobulin (Tg) levels and negative I-131 whole-body scan (WBS). Whole-body planar and cervico-thoracic tomographic scintigraphy (single-photon emission tomography-SPET) with Tc-99m depreotide was performed in a 68-year-old male patient suffering from PTC stage III, with a mild increase in serum Tg levels coupled with a recent negative I-131 WBS. The findings were compared with those of neck ultrasonography (US) and computerized tomography (CT). Nodal neck dissection and histopathology provided the definitive diagnosis. Tc-99m depreotide scanning revealed foci of cervical lymph node metastases, which did not accumulate I-131. The findings were in accordance with neck US and CT. Histopathology established the diagnosis of metastatic cervical lymph node PTC. Lymph node immunoreactivity was positive for the somatostatin receptor subtypes 2, 5 and 3. Scintigraphy with Tc-99m depreotide could prove a useful adjunct to the armamentarium for the follow-up of PTC, especially in the setting of detectable serum Tg and negative I-131 WBS.

    Topics: Aged; Carcinoma, Papillary, Follicular; Humans; Iodine Radioisotopes; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organotechnetium Compounds; Somatostatin; Thyroid Neoplasms

2006